Overview

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
0
Participant gender:
All
Summary
This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Desvenlafaxine Succinate
Criteria
Inclusion Criteria:

- Age >=7 and <18 years of age

- Primary diagnosis of major depressive disorder (MDD)

- CDRS-R score >40

Exclusion Criteria:

- History of suicidal behavior or requires precaution against suicide

- Not in generally healthy medical condition

- History of psychosis or bipolar disorder

- Seizure disorder